Eisai strikes Japan licensing deal with Shanghai Henlius Biotech

Core Viewpoint - Japan's Eisai has entered into a licensing agreement with Shanghai Henlius Biotech for the lung cancer drug Hansizhuang, involving an upfront payment of $75 million and potential milestone payments totaling up to $313.34 million [1] Group 1 - Eisai will pay an upfront fee of $75 million to Henlius for the licensing rights to Hansizhuang [1] - The agreement includes additional milestone payments that could reach up to $313.34 million, contingent on the achievement of specific targets [1] - This partnership highlights the growing collaboration between Japanese and Chinese biopharmaceutical companies in the oncology sector [1]